Rockline Wealth Management LLC Purchases 1,553 Shares of Johnson & Johnson (NYSE:JNJ)

Rockline Wealth Management LLC boosted its position in Johnson & Johnson (NYSE:JNJ) by 5.5% in the fourth quarter, Holdings Channel.com reports. The firm owned 29,965 shares of the company’s stock after buying an additional 1,553 shares during the quarter. Johnson & Johnson comprises approximately 1.2% of Rockline Wealth Management LLC’s investment portfolio, making the stock its 25th largest position. Rockline Wealth Management LLC’s holdings in Johnson & Johnson were worth $4,334,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently modified their holdings of JNJ. State Street Corp boosted its stake in Johnson & Johnson by 0.9% during the third quarter. State Street Corp now owns 134,245,811 shares of the company’s stock worth $21,755,874,000 after acquiring an additional 1,154,088 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Johnson & Johnson by 1.8% during the third quarter. Geode Capital Management LLC now owns 56,106,884 shares of the company’s stock valued at $9,064,149,000 after purchasing an additional 1,004,763 shares during the last quarter. FMR LLC boosted its position in shares of Johnson & Johnson by 7.4% in the 3rd quarter. FMR LLC now owns 18,316,920 shares of the company’s stock worth $2,968,440,000 after purchasing an additional 1,265,748 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in Johnson & Johnson by 0.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 17,639,368 shares of the company’s stock valued at $2,858,543,000 after buying an additional 102,502 shares in the last quarter. Finally, Franklin Resources Inc. raised its stake in Johnson & Johnson by 11.4% during the third quarter. Franklin Resources Inc. now owns 16,840,069 shares of the company’s stock valued at $2,721,355,000 after buying an additional 1,729,281 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling

In other news, Director Mark A. Weinberger acquired 1,000 shares of Johnson & Johnson stock in a transaction on Thursday, December 12th. The shares were acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the purchase, the director now directly owns 1,000 shares in the company, valued at $147,220. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $153.46 on Friday. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85. The stock’s 50-day simple moving average is $147.49 and its 200-day simple moving average is $156.08. The company has a market capitalization of $369.47 billion, a price-to-earnings ratio of 23.08, a PEG ratio of 2.44 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The business had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. During the same period last year, the firm posted $2.29 EPS. The company’s revenue was up 5.3% on a year-over-year basis. As a group, analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be issued a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.23%. Johnson & Johnson’s dividend payout ratio (DPR) is 74.59%.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Stifel Nicolaus reduced their price target on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a report on Thursday, January 23rd. Raymond James dropped their target price on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Guggenheim increased their target price on Johnson & Johnson from $162.00 to $166.00 and gave the company a “neutral” rating in a research note on Monday. Leerink Partners lowered their price target on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a report on Thursday, January 23rd. Finally, Bank of America decreased their target price on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a research report on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $170.67.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.